Academic Journal
Q1Cell Reports Medicine
About Cell Reports Medicine
Cell Reports Medicine is a scholarly journal published by Cell Press. SCImago 2025 places it in Q1 with an SJR of 4.932 and an H-index of 81.
Its listed coverage is 2020-2026 and its research categories include Biochemistry, Genetics and Molecular Biology (miscellaneous) (Q1). The 2025 dataset reports 449 documents and 11711 citations across the latest three-year reporting window.
Exploring Cell Reports Medicine: A Leading Open Access Journal in Translational Research
Cell Reports Medicine is a premier open-access journal from Cell Press, renowned for publishing high-quality, cutting-edge research in translational and clinical medicine. Launched to bridge the gap between basic biomedical science and clinical application, this journal serves as a valuable platform for researchers, clinicians, and healthcare professionals looking to stay at the forefront of medical innovation.
What is Cell Reports Medicine?
Cell Reports Medicine is part of the prestigious Cell family of journals and focuses on translational medicine—the field that transforms laboratory findings into therapeutic strategies that improve human health. It welcomes a wide range of research articles, reviews, and commentaries that explore the interface between biology and medicine.
The journal covers diverse areas such as:
-
Human pathophysiology
-
Clinical trials
-
Personalized medicine
-
Regenerative therapies
-
Digital health
-
Vaccine development
-
Infectious diseases and immunology
-
Oncology and cancer therapeutics
By prioritizing accessibility and scientific rigor, Cell Reports Medicine promotes global visibility and impact for researchers aiming to address complex health challenges.
Key Features of Cell Reports Medicine
1. Open Access Model:
As an open-access journal, Cell Reports Medicine ensures that all published content is freely available to a worldwide audience. This helps accelerate the dissemination of critical medical discoveries and supports knowledge sharing across disciplines and regions.
2. Rapid Publication:
The journal is known for its efficient peer review and publication process. This speed is vital in medical research, especially in fast-evolving fields such as infectious diseases, where timely access to information can influence patient outcomes and policy decisions.
3. Interdisciplinary Focus:
Cell Reports Medicine brings together research from molecular biology, genetics, pharmacology, bioinformatics, and clinical sciences. This multidisciplinary approach fosters collaboration and innovation in developing effective diagnostics, treatments, and preventive strategies.
4. High Editorial Standards:
Articles submitted to Cell Reports Medicine undergo rigorous peer review by experts in the field. The editorial board includes leading scientists and clinicians who ensure that only impactful, reproducible, and ethical research is published.
Why Publish in Cell Reports Medicine?
Publishing in Cell Reports Medicine offers numerous benefits:
-
Wide Reach and Visibility: Articles are indexed in major databases like PubMed, Scopus, and Web of Science, boosting visibility and citation potential.
-
Prestige and Recognition: Affiliated with Cell Press, the journal offers a stamp of excellence that enhances the reputation of contributing authors.
-
Engagement with a Global Audience: From academic researchers to healthcare providers and policymakers, the readership is diverse and engaged.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
Scope of Cell Reports Medicine: Advancements in Cell Therapy and Precision Medicine
Cell Reports Medicine is an innovative and influential journal that provides a comprehensive platform for the latest discoveries and insights in the rapidly evolving field of cell therapy, regenerative medicine, and precision medicine. As a significant publication within the scientific community, the journal covers cutting-edge research and findings that shape the future of healthcare. This article delves into the scope of Cell Reports Medicine, highlighting its contribution to the broader scientific landscape and the future of personalized medicine.
The Role of Cell Reports Medicine in Modern Healthcare
Cell Reports Medicine stands at the intersection of basic science and clinical applications, focusing on the development and implementation of cellular-based therapies for treating a variety of diseases. The journal’s scope extends to areas like stem cell research, gene editing, immune modulation, and cancer therapies, which are revolutionizing how physicians and researchers approach complex medical conditions.
One of the most significant areas the journal explores is cellular therapies. Cellular-based treatments, such as stem cell therapy, have shown great promise in addressing diseases that currently have limited treatment options, such as neurological disorders, heart disease, and autoimmune diseases. Cell Reports Medicine publishes research that provides evidence on the efficacy, safety, and ethical considerations of such therapies, helping to drive innovation in the field.
Another important aspect of the journal’s scope is its focus on gene editing technologies, particularly CRISPR-Cas9. This breakthrough tool has transformed the ability to manipulate genes within living organisms, paving the way for the development of more targeted treatments and cures. Cell Reports Medicine features studies on how gene editing can be used to correct genetic disorders, improve cancer therapies, and even advance the field of tissue regeneration.
Regenerative Medicine and Personalized Approaches
Regenerative medicine is a rapidly growing field that seeks to replace or regenerate damaged tissues and organs, offering new hope for patients with chronic diseases, injuries, or degenerative conditions. Cell Reports Medicine explores this field in-depth, with articles discussing advancements in stem cell biology, tissue engineering, and organ regeneration. These technologies are especially significant in creating personalized treatments for patients, as they enable therapies tailored to an individual's genetic profile.
By focusing on personalized medicine, Cell Reports Medicine offers a lens through which scientists can develop more targeted therapies that cater to the unique biological characteristics of each patient. This approach ensures higher success rates in treatments and reduces the risk of adverse side effects.
Precision Medicine: A New Frontier in Disease Treatment
Precision medicine, an area that Cell Reports Medicine emphasizes, is changing the way healthcare providers approach disease diagnosis and treatment. By utilizing genetic, environmental, and lifestyle factors, precision medicine allows for the creation of customized treatment plans that are more effective and less harmful than traditional methods. The journal features groundbreaking research on how genomics and bioinformatics can guide personalized treatment plans for a range of diseases, from cancer to metabolic disorders.
As the journal continues to publish studies and breakthroughs in this area, it plays a pivotal role in fostering the advancement of precision medicine. This personalized approach is not only improving patient outcomes but also reducing healthcare costs and the burden on medical systems worldwide.
Conclusion: Cell Reports Medicine’s Contribution to the Future of Medicine
Cell Reports Medicine remains at the forefront of research in cell therapy, regenerative medicine, and precision medicine. Its focus on cellular-based therapies, gene editing, stem cell research, and personalized approaches underscores the journal’s dedication to advancing healthcare and improving patient outcomes. As the field of medical research continues to evolve, Cell Reports Medicine will undoubtedly continue to serve as a vital resource for researchers, clinicians, and healthcare professionals around the world, paving the way for a future where diseases are treated with precision and personalized therapies.
In conclusion, Cell Reports Medicine is not just a journal; it is a platform for transformative discoveries that are revolutionizing the world of medicine.
Recent Research Articles
Latest publications matched automatically by ISSN.
LungGPT: A unified multimodal system for interpretable diagnosis and clinical decision support of respiratory diseases
Jun Shao, Xingting Liu, Zhihan Zhang, Shu Liao et al.
2026-09 · DOI: 10.1016/j.xcrm.2026.102926Fast tumor accumulation and payload release of c-Met targeting aptamer-drug conjugate enables robust anti-tumor efficacy
Yuan Liu, Jiaxuan He, Minhui Su, Honghong Yang et al.
2026-09 · DOI: 10.1016/j.xcrm.2026.103005Surface display of co-stimulatory ligand B7H2 on engineered bacteria enhances tumor immunotherapy
Qiliner Feng, Chen Wang, Zexi Li, Dingran Sheng et al.
2026-09 · DOI: 10.1016/j.xcrm.2026.103016CRISPRa-identified transcription factors reprogram glioblastoma into dendritic cell-like cells to elicit systemic antitumor immunity
Xiao Liu, Maorong Zhu, Cheng Zou, Zhengcong Cao et al.
2026-09 · DOI: 10.1016/j.xcrm.2026.103018Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitor
Devra J. Olson, Bernard A. Liu, Patrick Younan, Gabriele Blahnik-Fagan et al.
2026-09 · DOI: 10.1016/j.xcrm.2026.103021Preferential engagement of the anti-inflammatory ATP/adenosine axis by HIV vaccine candidate with V1-deleted envelope in male rhesus macaques
Isabela Silva de Castro, Mohammad Arif Rahman, Massimiliano Bissa, Katherine C. Goldfarbmuren et al.
2026-09 · DOI: 10.1016/j.xcrm.2026.103022Dendritic cell centric nanoengineering couples antigen acquisition and STING activation for cancer immunotherapy
Shuting Xiang, Shanshan Ma, Tuzhi Xu, Wenwen Yu et al.
2026-09 · DOI: 10.1016/j.xcrm.2026.103025Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis
Federica Tavaglione, Rohit Loomba
2026-09 · DOI: 10.1016/j.xcrm.2026.103023Transforming large language models into medical specialists via knowledge injection
Kiduk Kim, Jeong Min Song, Dong Yeong Kim, Yoojin Nam et al.
2026-09 · DOI: 10.1016/j.xcrm.2026.103020Maternal secretor status and human milk oligosaccharides influence the infant gut resistome
Anna Samarra, Alejandro J. Alcañiz, Narciso M. Quijada, Simone Renwick et al.
2026-09 · DOI: 10.1016/j.xcrm.2026.103007A biomimetic hybrid membrane vesicle nanoplatform attenuates tendinopathy through neuroinflammation modulation and tendon regeneration
Dongxu Li, Wei Huang, Feifei Ni, Wenbo Yang et al.
2026-08 · DOI: 10.1016/j.xcrm.2026.102937CDK8/19 inhibition prevents adaptive resistance to CDK4/6 inhibitors in vitro and in vivo
Zachary T. Mack, Margarita Yastrebova, Chang-uk Lim, Xiaokai Ding et al.
2026-08 · DOI: 10.1016/j.xcrm.2026.103004Early-life immune imprinting by a B. infantis-HMO synbiotic shapes infant immune signatures and protects against experimental respiratory disease
Ridwan B. Rashid, Cheong Kwong Chung, Patricia Namubiru, Tufael Ahmed et al.
2026-08 · DOI: 10.1016/j.xcrm.2026.102935EGFR inhibition promotes functional engraftment and graft survival via donor-derived CHI3L1 in fetal RPE suspension transplantation
Xiying Mao, Wenjie Yin, Miao Xu, Zixuan Niu et al.
2026-08 · DOI: 10.1016/j.xcrm.2026.102963A unified framework and benchmark for generalizable biomedical knowledge extraction and applications with large language models
Wuyang Lan, Siqi Zhang, Wenzheng Wang, Ke Hu et al.
2026-08 · DOI: 10.1016/j.xcrm.2026.102975Köhlmeier-Degos disease is an interferonopathy characterized by type I and II interferon-driven inflammatory vasculopathy
Cornelia D. Cudrici, Shubham Goel, Keiko Sakamoto, Seon-Pil Jin et al.
2026-08 · DOI: 10.1016/j.xcrm.2026.102947Spinal cord stimulation modulates post-synaptic inhibition to improve arm neuromotor control after chronic stroke
Luigi Borda, Nikhil Verma, Erynn Sorensen, Erick Carranza et al.
2026-08 · DOI: 10.1016/j.xcrm.2026.102925Prevention of myopia in a near-primate by supplemental indigo light suggests a hypothesis for the myopia boom
Rafael Grytz, Mustapha El Hamdaoui, Takahiro Yamashita, Shane P. D'Souza et al.
2026-08 · DOI: 10.1016/j.xcrm.2026.102999Phase 1 study of intracranial T cell therapy with pemetrexed for refractory brain metastases and glioblastomas
Congcong Li, Shuang Wang, Xiumei Rong, Chuxiong Zeng et al.
2026-08 · DOI: 10.1016/j.xcrm.2026.102967Persistent cytolytic CD8+ T cells recognize SARS-CoV-2 and herpesvirus epitopes in long COVID
Tongcui Ma, Heeju Ryu, Kailin Yin, Thomas Dalhuisen et al.
2026-08 · DOI: 10.1016/j.xcrm.2026.102946Reviews
Community Reviews
Version History
April 23, 2025 at 11:04 am
April 23, 2025